Related Experiment Video
Updated: Jun 28, 2025

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Serotonin syndrome treated with cyproheptadine using NPi from a digital pupillometer as a therapeutic indicator: A
Kazuki Sugaya1, Tomotaka Misawa1, Makoto Onodera2
1Department of Emergency Medicine, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.
Rationale:
Serotonin syndrome is a potentially life-threatening condition resulting from the use of antidepressants, their interactions with other serotonergic medications, or poisoning. It presents with a triad of psychiatric, dysautonomic, and neurological symptoms and is sometimes fatal. While cyproheptadine is a specific treatment option, the optimal duration of its administration remains unclear. The purpose of this report is to quantitatively assess the endpoints of serotonin syndrome treatment. Based on the hypothesis that neurological pupil index (NPi) on a digital pupil recorder would correlate with the severity of the serotonin syndrome, we administered cyproheptadine using NPi as an indicator.
Patient Concerns:
A patient with a history of depression was brought to our hospital after he overdosed on 251 tablets of serotonin and noradrenaline reuptake inhibitors.
Diagnoses:
On day 3, the patient was diagnosed with serotonin syndrome.
Interventions:
Cyproheptadine syrup was administered at 4 mg every 4 hours. The NPi of the automated pupillometer was simultaneously measured. On day 5, the NPi exceeded 3.0 cyproheptadine was discontinued.
Outcomes:
The patient was discharged on day 7.
Lessons:
The lack of considerable improvement during the treatment period suggests that the patient may have improved on his own. In this case, the relationship between NPi and the severity of serotonin syndrome could not be determined.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Management of Insomnia
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
G-protein Coupled Receptors

